COST-EFFECTIVENESS ANALYSIS ON STARTING PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON A HIGHLY POTENT TYROSINE KINASE INHIBITOR AND EARLY SWITCHING TO IMATINIB
Abstract
Authors
U Rochau D Vukicevic S Schmidt D Stenehjem D Brixner J Radich G Gastl U Siebert